{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:58Z","timestamp":1787032858045,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,29]]},"DOI":"10.7759\/cureus.85052","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T18:58:16Z","timestamp":1748545096000},"source":"Crossref","is-referenced-by-count":2,"title":["Atypical Femoral Fracture During Long-Term Treatment With Denosumab in Patients With Metastatic Bone Tumors"],"prefix":"10.7759","author":[{"given":"Yuka","family":"Aimono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomiko","family":"Sunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Tsuboya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Kogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ako","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen LS","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, et al.. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003, 98:1735-44. 10.1002\/cncr.11701","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck AT","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, et al.. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010, 28:5132-9. 10.1200\/JCO.2010.29.7101","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0192","article-title":"Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy","volume":"22","author":"Yang SP","year":"2017","unstructured":"Yang SP, Kim TW, Boland PJ, Farooki A. Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy. Oncologist. 2017, 22:438-44. 10.1634\/theoncologist.2016-0192","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina CV","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005, 90:1294-301. 10.1210\/jc.2004-0952","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane E","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR, et al.. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010, 25:2267-94. 10.1002\/jbmr.253","journal-title":"J Bone Miner Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2016.1277412","article-title":"Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab","volume":"88","author":"Austin DC","year":"2017","unstructured":"Austin DC, Torchia MT, Klare CM, Cantu RV. Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab. Acta Orthop. 2017, 88:351-3. 10.1080\/17453674.2016.1277412","journal-title":"Acta Orthop"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002058","article-title":"Impending atypical femoral fracture in a patient of breast cancer with bone metastases receiving long-term denosumab","volume":"43","author":"Sugihara T","year":"2018","unstructured":"Sugihara T, Koizumi M, Hayakawa K, Ito Y, Sata N. Impending atypical femoral fracture in a patient of breast cancer with bone metastases receiving long-term denosumab. Clin Nucl Med. 2018, 43:365-6. 10.1097\/RLU.0000000000002058","journal-title":"Clin Nucl Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler RA","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, et al.. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016, 31:16-35. 10.1002\/jbmr.2708","journal-title":"J Bone Miner Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.99B3.BJJ-2016-0276.R2","article-title":"Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management","volume":"99-B","author":"Koh A","year":"2017","unstructured":"Koh A, Guerado E, Giannoudis PV. Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. Bone Joint J. 2017, 99-B:295-302. 10.1302\/0301-620X.99B3.BJJ-2016-0276.R2","journal-title":"Bone Joint J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0910389","article-title":"Atypical femoral fractures and bisphosphonate use","volume":"362","author":"Girgis CM","year":"2010","unstructured":"Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med. 2010, 362:1848-9. 10.1056\/NEJMc0910389","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100259","article-title":"Atypical femoral fractures from bisphosphonate in cancer patients - review","volume":"18","author":"Lockwood M","year":"2019","unstructured":"Lockwood M, Banderudrappagari R, Suva LJ, Makhoul I. Atypical femoral fractures from bisphosphonate in cancer patients - review. J Bone Oncol. 2019, 18:100259. 10.1016\/j.jbo.2019.100259","journal-title":"J Bone Oncol"},{"key":"ref13","unstructured":"FDA drug safety communication. safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. (2019). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-safety-update-osteoporosis-drugs...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100301","article-title":"Incidence of atypical femoral fractures in the treatment of bone metastasis: an alert report","volume":"23","author":"Kaku T","year":"2020","unstructured":"Kaku T, Oh Y, Sato S, et al.. Incidence of atypical femoral fractures in the treatment of bone metastasis: an alert report. J Bone Oncol. 2020, 23:100301. 10.1016\/j.jbo.2020.100301","journal-title":"J Bone Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358257-atypical-femoral-fracture-during-long-term-treatment-with-denosumab-in-patients-with-metastatic-bone-tumors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T18:58:17Z","timestamp":1748545097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358257-atypical-femoral-fracture-during-long-term-treatment-with-denosumab-in-patients-with-metastatic-bone-tumors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.85052","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}